{"id":52,"date":"2026-08-27T13:14:43","date_gmt":"2026-08-27T13:14:43","guid":{"rendered":"https:\/\/test.rhino-health.org\/aztec-trial\/"},"modified":"2026-08-27T13:14:43","modified_gmt":"2026-08-27T13:14:43","slug":"aztec-trial","status":"publish","type":"page","link":"https:\/\/rhino-health.org\/?page_id=52","title":{"rendered":"AZTEC Trial"},"content":{"rendered":"<section class=\"az-about-hero\">\n<div class=\"az-wrap az-about-grid\">\n<div>\n<div class=\"az-eyebrow\">The AZTEC Trial<\/div>\n<h1>Why was AZTEC needed?<\/h1>\n<p class=\"az-lead\">Babies born very preterm are at increased risk of chronic lung disease because their lungs are still developing and can be exposed to inflammation, respiratory support and infection during a critical period of lung growth.<\/p>\n<p>AZTEC was designed to test whether azithromycin could target both inflammation and organisms such as <em>Ureaplasma<\/em>, and thereby improve important lung outcomes.<\/p>\n<div class=\"az-btns\"><a class=\"az-btn az-btn--primary\" href=\"https:\/\/rhino-health.org\/results\/\">See what AZTEC found \u2192<\/a><a class=\"az-btn az-btn--ghost\" href=\"https:\/\/rhino-health.org\/families\/\">Information for families<\/a><\/div>\n<\/div>\n<div class=\"az-owned-image-shell\"><img decoding=\"async\" class=\"az-owned-image\" src=\"https:\/\/rhino-health.org\/wp-content\/themes\/aztec-2026-editable\/assets\/images\/home-hero-hq.webp\" alt=\"Premature baby receiving neonatal intensive care\" loading=\"lazy\"><\/div>\n<\/div>\n<\/section>\n<section class=\"az-section\">\n<div class=\"az-wrap\">\n<div class=\"az-eyebrow\">The clinical problem<\/div>\n<h2>Chronic lung disease of prematurity<\/h2>\n<p class=\"az-lead\">Chronic lung disease of prematurity, often termed bronchopulmonary dysplasia (BPD), remains one of the most important complications of very preterm birth. Some affected babies need oxygen or respiratory support for prolonged periods and respiratory problems can persist after discharge.<\/p>\n<div class=\"az-grid3\">\n<article class=\"az-card\">\n<h3>Interrupted lung development<\/h3>\n<p>Very preterm birth occurs during rapid growth of the airways, air sacs and pulmonary blood vessels.<\/p>\n<\/article>\n<article class=\"az-card\">\n<h3>Inflammation<\/h3>\n<p>Inflammatory pathways are implicated in lung injury and impaired lung development.<\/p>\n<\/article>\n<article class=\"az-card\">\n<h3>Microbiology<\/h3>\n<p><em>Ureaplasma<\/em> and other organisms may influence inflammatory responses and risk of chronic lung disease.<\/p>\n<\/article>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"az-section az-section--soft\">\n<div class=\"az-wrap\">\n<div class=\"az-eyebrow\">Trial design<\/div>\n<h2>How did AZTEC work?<\/h2>\n<p class=\"az-lead\">AZTEC was a multicentre, randomised, double-blind, placebo-controlled trial. Babies were allocated to azithromycin or placebo, with treatment started early after birth and given for 10 days.<\/p>\n<div class=\"az-page-image az-illustration\"><img decoding=\"async\" src=\"https:\/\/rhino-health.org\/wp-content\/themes\/aztec-2026-editable\/assets\/images\/trial-pathway.svg\" alt=\"Diagram of the AZTEC randomised controlled trial pathway\" loading=\"lazy\"><\/div>\n<div class=\"az-grid3\">\n<article class=\"az-card\">\n<h3>Who could take part?<\/h3>\n<p>Infants born before 30 weeks\u2019 gestation receiving neonatal intensive care were considered against the trial eligibility criteria.<\/p>\n<\/article>\n<article class=\"az-card\">\n<h3>What was compared?<\/h3>\n<p>Intravenous azithromycin was compared with a matched placebo so families and clinical\/research teams remained blinded to treatment allocation.<\/p>\n<\/article>\n<article class=\"az-card\">\n<h3>What was measured?<\/h3>\n<p>The primary outcome was survival without physiologically defined moderate or severe chronic lung disease at 36 weeks\u2019 postmenstrual age.<\/p>\n<\/article>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"az-section\">\n<div class=\"az-wrap\">\n<div class=\"az-eyebrow\">Biological samples<\/div>\n<h2>Understanding mechanisms as well as clinical outcomes<\/h2>\n<p class=\"az-lead\">AZTEC incorporated microbiological and laboratory studies alongside the clinical trial. Respiratory and stool samples enabled investigators to examine <em>Ureaplasma<\/em>, inflammatory pathways, the microbiome and antimicrobial resistance.<\/p>\n<div class=\"az-history-grid\">\n<article class=\"az-card\">\n<h3>Respiratory samples<\/h3>\n<p>Where possible, small airway samples were obtained during routine neonatal care and used to study organisms and inflammatory mediators.<\/p>\n<\/article>\n<article class=\"az-card\">\n<h3>Stool samples<\/h3>\n<p>Gut microbiology and macrolide resistance were investigated, providing important information on antimicrobial-resistance consequences of neonatal antibiotic exposure.<\/p>\n<\/article>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"az-section az-section--soft\">\n<div class=\"az-wrap\">\n<div class=\"az-eyebrow\">Scale &#038; collaboration<\/div>\n<h2>A UK-wide neonatal research partnership<\/h2>\n<p class=\"az-lead\">799 babies were recruited across 28 neonatal intensive care units. The trial was led from Cardiff University and coordinated by the Centre for Trials Research, with collaborators from neonatal centres and universities across the UK.<\/p>\n<div class=\"az-team-grid\">\n<div class=\"az-card az-team-card\">\n<h3>Chief Investigator<\/h3>\n<p><strong>Professor Sailesh Kotecha<\/strong><br \/>Department of Child Health, Cardiff University<\/p>\n<\/div>\n<div class=\"az-card az-team-card\">\n<h3>Trial coordination<\/h3>\n<p><strong>Centre for Trials Research<\/strong><br \/>Cardiff University<\/p>\n<\/div>\n<div class=\"az-card az-team-card\">\n<h3>Collaborators<\/h3>\n<p>Co-applicants and investigators included teams from Newcastle, Leicester, Liverpool, UCL, Imperial College London and participating neonatal units throughout the UK.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"az-section az-section--warm\">\n<div class=\"az-wrap\">\n<div class=\"az-eyebrow\">Funding &#038; governance<\/div>\n<h2>How was the study supported?<\/h2>\n<p class=\"az-lead\">AZTEC was funded by the NIHR Health Technology Assessment Programme (HTA Project 16\/111\/106) and registered as ISRCTN11650227.<\/p>\n<p>The trial received the relevant UK research ethics, Health Research Authority and medicines-regulatory approvals.<\/p>\n<div class=\"az-btns\"><a class=\"az-btn az-btn--ghost\" href=\"https:\/\/rhino-health.org\/researchers\/\">Protocols and research resources \u2192<\/a><\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>The AZTEC Trial Why was AZTEC needed? Babies born very preterm are at increased risk of chronic lung disease because their lungs are still developing and can be exposed to inflammation, respiratory support and infection during a critical period of lung growth. AZTEC was designed to test whether azithromycin could target both inflammation and organisms [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-52","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/rhino-health.org\/index.php?rest_route=\/wp\/v2\/pages\/52","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rhino-health.org\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rhino-health.org\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rhino-health.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rhino-health.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52"}],"version-history":[{"count":0,"href":"https:\/\/rhino-health.org\/index.php?rest_route=\/wp\/v2\/pages\/52\/revisions"}],"wp:attachment":[{"href":"https:\/\/rhino-health.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}